In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Palvella Therapeutics (PVLA – Research Report), with a price target of $52.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Whitney Ijem has given his Buy rating due to a combination of factors surrounding Palvella Therapeutics’ promising developments. The completion of enrollment for the Phase 3 SELVA trial of QTORIN rapamycin, which exceeded its target, demonstrates the company’s strong execution capabilities. This trial, designed with significant statistical power, is expected to yield positive topline results in the first quarter of 2026, reinforcing confidence in the company’s strategic direction.
Furthermore, the Phase 2 trial results showed that QTORIN rapamycin was well-tolerated with no serious adverse events and demonstrated significant clinical improvements, which bodes well for the Phase 3 outcomes. The potential market impact is substantial, with projected peak sales exceeding $550 million by 2031, assuming a successful launch in 2027. These factors collectively underpin the Buy rating, highlighting the company’s potential for growth and value creation.
In another report released on June 10, Scotiabank also maintained a Buy rating on the stock with a $50.00 price target.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PVLA in relation to earlier this year.